AI-Assisted Scoring Improves Interobserver Agreement in Breast Cancer Biomarker Evaluation.

Wiebke Solass¹, Clara Desteffani¹, Florin Kalberer¹, Ben Scattolo¹, Branislav Zagrapan¹, Donna Mulkern², Peter Caie², Martin Wartenberg¹, Inti Zlobec^1,3, Meredith Lodge²

¹Institute of Tissue Medicine and Pathology (ITMP), University of Bern, 3008 Bern, Switzerland.

²Indica Labs, Albuquerque, NM 87109, USA.

³Department Digital Medicine, University of Bern, 3008 Bern, Switzerland.

PubMed PMC DOI PDF

Abstract

Background: Immunohistochemical assessment of estrogen receptor (ER), progesterone receptor (PR), proliferation marker Ki67, and human epidermal growth factor receptor 2 (HER2) represents a central component of the diagnostic workflow in invasive breast carcinoma, directly influencing therapeutic decision-making, prognosis, and patient management. In this study, we evaluated the use of Indica Labs…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.